Locations:
Search IconSearch
April 12, 2021/Neurosciences

Characteristics of CNS Vasculitis Appear to Vary According to Affected Vessel Size

Differences between large-medium vessel and small vessel variants

Imaging of vessels in CNS vasculitis

By Ken Uchino, MD, Leonard Calabrese, DO, and Rula Hajj-Ali, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Arriving at a diagnosis of central nervous system vasculitis (CNS-V) is fraught with challenges. Clinical presentation can be quite variable, and there is no classic presentation. Further complicating matters, the condition has several mimics, brain tissue is inaccessible and there is no disease-specific test. However, advances in neuroimaging and next-generation sequencing — along with the involvement of a multidisciplinary clinical team — have added formidably to our knowledge of CNS-V.

Recently, two different disease subtypes have been postulated: the small vessel variant (SVV) and large-medium vessel variant (LMVV).1 We sought to clarify the clinical characteristics, brain MRI findings and diagnostic accuracy of high-resolution vessel wall image (HR-VWI) and brain biopsy according to the affected vessel size in CNS-V patients. We discuss the results of this study in a poster presented at ACR Convergence 2020.2

Distinguishing between LMVV and SVV

Using Cleveland Clinic’s CNS vasculopathy registry, we identified 34 CNS-V patients who underwent digital subtraction angiography (DSA) or magnetic resonance angiography (MRA) at our institution from 2012-2019. For this study, patients with cerebral vasculature indicating vasculitis in proximal or middle arterial segments had LMVV, and patients with only smaller distal branch vessel involvements or normal angiography had SVV.

Based on angiographical findings, 11 (32.4%) of the patients in our cohort were LMVV and 23 (67.6%) were SVV. Patients with LMVV had more infarcts and were more likely to have concentric vessel wall enhancement (VWE) on HR-VWI, as shown in Table 1. Meningeal/parenchymal contrast enhancement of lesion was more frequently observed in the SVV group, and the majority of patients in this group were diagnosed by brain biopsy, as shown in Table 2. Brian biopsy was positive in 100% of patients with SVV compared with only 57.1% in patients with LMVV.

Advertisement

Table 1. Brain MRI, cerebral angiogram and HR-VWI findings in CNS-V patients (LMVV vs. SVV)

MRI findings, n (%)
LMVV(n = 11)
SVV(N = 23)
P Value
Brain infarcts
LMVV(n = 11)
11 (100.0)
SVV(N = 23)
14 (60.9)
P Value
0.017
Parenchymal hemorrhage
LMVV(n = 11)
1 (9.1)
SVV(N = 23)
5 (21.7)
P Value
0.638
Subarachnoid hemorrhage
LMVV(n = 11)
0 (0.0)
SVV(N = 23)
4 (17.4)
P Value
0.280
White matter lesion
LMVV(n = 11)
2 (18.2)
SVV(N = 23)
12 (52.2)
P Value
0.076
Tumor-like lesion
LMVV(n = 11)
0 (0.0)
SVV(N = 23)
8 (34.8)
P Value
0.034
Contract enhancement lesion
LMVV(n = 11)
5 (45.5)
SVV(N = 23)
20 (87.0)
P Value
0.033
Assessment of the cerebral vascular image, n (%)
LMVV(n = 11)
SVV(N = 23)
P Value
Both MRA and DSA
LMVV(n = 11)
11 (100.0)
SVV(N = 23)
13 (56.5)
P Value
0.014
Only MRA
LMVV(n = 11)
0 (0.0)
SVV(N = 23)
8 (34.8)
P Value
0.034
Only DSA
LMVV(n = 11)
0 (0.0)
SVV(N = 23)
2 (8.7)
P Value
1.000
Arterial stenosis, n (%)
LMVV(n = 11)
SVV(N = 23)
P Value
Proximal segment
LMVV(n = 11)
7 (63.6)
SVV(N = 23)
0 (0.0)
P Value
< 0.001
Middle segment
LMVV(n = 11)
10 (90.9)
SVV(N = 23)
0 (0.0)
P Value
< 0.001
Smaller distal branch
LMVV(n = 11)
10 (90.0)
SVV(N = 23)
8 (34.8)
P Value
0.003
None
LMVV(n = 11)
0 (0.0)
SVV(N = 23)
15 (62.5)
P Value
< 0.001
HR-VWI findings, n (%)
LMVV(n = 11)
SVV(N = 23)
P Value
VWE
LMVV(n = 11)
10 (100.0) [n = 10]
SVV(N = 23)
2 (14.2) [n = 14]
P Value
< 0.001
Concentric VWE
LMVV(n = 11)
9 (90.0) [n = 10]
SVV(N = 23)
1 (7.1) [n = 14]
P Value
< 0.001
Eccentric VWE
LMVV(n = 11)
1 (10.0)[n = 10]
SVV(N = 23)
1 (7.1) [n = 14]
P Value
1.000

Notes: LMVV = large-medium vessel variant; SVV = small vessel variant; MRA = magnetic resonance angiography; DSA = digital subtraction angiography; HR-VWI = high-resolution vessel wall image; VWE = vessel wall enhancement

Table 2. Brain biopsy and CSF findings in CNS-V patients (LMVV vs. SVV)

Biopsy proven CNS-V, n (%)
LMVV(n = 11)
4 (36.4)
SVV( n = 23)
18 (78.3)
P Value
0.026
Biopsy positive, n (%)
LMVV(n = 11)
4 (57.1) [n = 7]
SVV( n = 23)
18 (100.0) [n = 18]
P Value
0.015
Pathological patterns, n (%)
LMVV(n = 11)
SVV( n = 23)
P Value
Granulomatous vasculitis
LMVV(n = 11)
1 (14.3) [n = 7]
SVV( n = 23)
1 (11.1) [n = 18]
P Value
0.490
Lymphocytic vasculitis
LMVV(n = 11)
3 (42.9) [n = 7]
SVV( n = 23)
12 (66.7) [n = 18]
P Value
0.378
Necrotizing vasculitis
LMVV(n = 11)
0 (0.0) [n = 7]
SVV( n = 23)
5 (27.8) [n = 18]
P Value
0.274
CSF findings, n (%)
LMVV(n = 11)
SVV( n = 23)
P Value
Abnormal*
LMVV(n = 11)
11 (100.0) [n = 11]
SVV( n = 23)
16 (80.0) [n = 20]
P Value
0.269
Pleocytosis*
LMVV(n = 11)
10 (90.9) [ n = 11]
SVV( n = 23)
12 (60.0) [n = 20]
P Value
0.106
Elevated protein*
LMVV(n = 11)
8 (72.7) [n = 11]
SVV( n = 23)
13 (65.0) [n = 20]
P Value
1.000

Notes: CSF = cerebral spinal fluid; SNS-V = central nervous system vasculitis; LMVV = large/medium vessel variant; SVV = small vessel variant.
*Abnormal CSF is defined by either leukocyte counts > 5 cells/mm3 (pleocytosis) or protein level > 45 mg/dl (elevated protein).

Arriving at a diagnosis of CNS-V

Diagnostic approach for CNS-V depends on the affected vessel size. In LMVV patients, the diagnosis of CNS-V is mainly based on evidence of concentric VWE on HR-VWI. By contrast, brain biopsy should be considered in patients with suspected SVV CNS-V if parenchymal enhancement of lesion is detected. In patients without VWE on HR-VWI and targeting contrast enhancement lesion, careful assessments including CSF abnormalities, DSA findings and clinical pictures are needed for the diagnosis of the CNS-V.

We take a systematic approach to the work-up of any patient suspected to have CNS-V. This approach includes a general history and physical exam, with a thorough review of symptoms associated with systemic autoimmune disease. Clinicians should look for infectious and/or malignant conditions that might be associated with many of these nonspecific symptoms, especially fever, malaise, joint pains and weight loss. When CNS-V is suspected, brain biopsy is of high yield.

References

  1. Thaler C, Kaufmann-Bühler AK, Gansukh T, et al. Neuroradiologic Characteristics of Primary Angiitis of the Central Nervous System According to the Affected Vessel Size. Clin Neuroradiol. 2019;29(1):37-44.
  2. Shimoyama T, Uchino K, Calabrese L, Hajj-ali R. Clinical Characteristics, Brain MRI Findings, and Diagnostic Approach of the Central Nervous System Vasculitis by Affected Vessel Size [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).

Advertisement

Related Articles

platelets flowing through blood vessel
Early Therapeutic Anticoagulation After Cranial Surgery Raises Risk of Intracranial Hemorrhage

Case series links catastrophic outcomes to therapy initiation within 48 hours post-procedure

gut-brain axis
Assessing Alzheimer’s Disease Drug Targets Along the Gut-Brain Axis

Pairing machine learning with multi-omics revealed potential therapeutic targets

anatomic spine with vectors displayed
Novel ‘Global Shear Vector’ Metric Provides New Insights Into Spinal Alignment

Tool correlates well with sagittal vertical axis and quality-of-life measures

woman grabbing her back in pain
June 3, 2024/Neurosciences/Podcast
Shedding Light on Stiff Person Syndrome (Podcast)

Heightened awareness of this rare disorder may lead to better diagnosis and treatment progress

deep brain stimulation of dentate nucleus
Deep Brain Stimulation After Stroke: What Underlies Improved Motor Function?

EDEN analysis investigates electrophysiological changes after continuous dentate nucleus stimulation

pills, syringes and vials on a tabletop
May 15, 2024/Neurosciences/Podcast
Multiple Sclerosis Medications: Making the Most of a Multitude of Options (Podcast)

Insights on the decision process for selecting a treatment approach

neurosurgeon performing minimally invasive spine operation
Top Takeaways From the 2024 AANS Annual Meeting

Scientific program chair reflects on what may resonate longest from this year’s neurosurgery conference

central vein sign on a brain MRI
CAVS-MS Advances Quest to Improve the Diagnosis of Multiple Sclerosis

New reports focus on neuroimaging biomarkers and features of atypical presentations

Ad